1575 related articles for article (PubMed ID: 8141877)
61. Combined chemotherapy plus radiotherapy for treatment of early-stage intermediate- and high-grade non-Hodgkin's lymphoma.
Briggs JH; Miller TP
Curr Oncol Rep; 2000 Mar; 2(2):176-81. PubMed ID: 11122841
[TBL] [Abstract][Full Text] [Related]
62. Presenting features, natural history, and prognostic factors in localized non-Hodgkin's lymphomas: analysis of 117 cases from a single institution.
Esteve J; López-Guillermo A; Martínez-Francés A; Bosch F; Terol MJ; Campo E; Montserrat E; Rozman C
Eur J Haematol; 1995 Oct; 55(4):217-22. PubMed ID: 7589337
[TBL] [Abstract][Full Text] [Related]
63. Non-Hodgkin's lymphoma of the thyroid.
Makepeace AR; Fermont DC; Bennett MH
Clin Radiol; 1987 May; 38(3):277-81. PubMed ID: 3581670
[TBL] [Abstract][Full Text] [Related]
64. [Prognosis factors analysis of 56 cases of non-Hodgkin's lymphoma originating from the nasopharynx].
Li SD; Ba YP; Zhang PW
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jul; 33(7):651-653. PubMed ID: 31327206
[No Abstract] [Full Text] [Related]
65. [Effect of L-Type Amino Acid Transporter 1 Expression on Clinicopathological Features and Prognosis of Non-Hodgkin's Lymphoma].
Zhao ZF; Hao XJ; Yang YM; Xu WG; Zhang YX; Yuan XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):434-438. PubMed ID: 38660848
[TBL] [Abstract][Full Text] [Related]
66. T-cell phenotype is associated with decreased survival in non-Hodgkin's lymphoma.
Shimizu K; Hamajima N; Ohnishi K; Hara K; Kunii A
Jpn J Cancer Res; 1989 Aug; 80(8):720-6. PubMed ID: 2511177
[TBL] [Abstract][Full Text] [Related]
67. The challenge of p53 as prognostic and predictive factor in Hodgkin's or non-Hodgkin's lymphoma.
Nieder C; Petersen S; Petersen C; Thames HD
Ann Hematol; 2001 Jan; 80(1):2-8. PubMed ID: 11233771
[TBL] [Abstract][Full Text] [Related]
68. Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis.
Recht L; Straus DJ; Cirrincione C; Thaler HT; Posner JB
Am J Med; 1988 Mar; 84(3 Pt 1):425-35. PubMed ID: 3348245
[TBL] [Abstract][Full Text] [Related]
69. Risk-adjusted prognostic models for Hodgkin's disease (HD) and grade II non-Hodgkin's lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients.
Low SE; Horsman JM; Walters SJ; Hancock H; Smith P; Linch D; Hancock BW
Br J Haematol; 2003 Jan; 120(2):277-80. PubMed ID: 12542487
[TBL] [Abstract][Full Text] [Related]
70. Follicular low-grade non-Hodgkin's lymphoma: long-term outcome with or without tumor progression.
Ersbøll J; Schultz HB; Pedersen-Bjergaard J; Nissen NI
Eur J Haematol; 1989 Feb; 42(2):155-63. PubMed ID: 2917634
[TBL] [Abstract][Full Text] [Related]
71. Non-Hodgkin's lymphoma in patients 70 years of age or older: factors associated with survival.
Cuttner J; Wallenstein S; Troy K
Leuk Res; 2002 May; 26(5):447-50. PubMed ID: 11916517
[TBL] [Abstract][Full Text] [Related]
72. Causes of death in children diagnosed with non-Hodgkin's lymphoma between 1974 and 1985.
Robertson CM; Stiller CA; Kingston JE
Arch Dis Child; 1992 Nov; 67(11):1378-83. PubMed ID: 1471892
[TBL] [Abstract][Full Text] [Related]
73. Survival following combination chemotherapy in advanced high grade non-Hodgkin's lymphomas: relation to proliferative activity of the lymphoma cells.
Brandt L; Olsson H
Eur J Haematol; 1987 May; 38(5):437-41. PubMed ID: 3653366
[TBL] [Abstract][Full Text] [Related]
74. Non-Hodgkin's lymphoma in northern Sweden. Prognostic factors and response to treatment.
Osterman B; Jonsson H; Tavelin B; Lenner P
Acta Oncol; 1993; 32(5):507-15. PubMed ID: 8217234
[TBL] [Abstract][Full Text] [Related]
75. The role of radiotherapy in the treatment of localised intermediate and high grade non-Hodgkin's lymphoma in elderly patients.
Wylie JP; Cowan RA; Deakin DP
Radiother Oncol; 1998 Oct; 49(1):9-14. PubMed ID: 9886691
[TBL] [Abstract][Full Text] [Related]
76. T-cell-rich B-cell lymphoma.
Rodriguez J; Pugh WC; Cabanillas F
Blood; 1993 Sep; 82(5):1586-9. PubMed ID: 8364208
[TBL] [Abstract][Full Text] [Related]
77. A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin's lymphoma.
Steward WP; Todd ID; Harris M; Jones JM; Blackledge G; Wagstaff J; Anderson H; Wilkinson PM; Crowther D
Eur J Cancer Clin Oncol; 1984 Jul; 20(7):881-9. PubMed ID: 6547675
[TBL] [Abstract][Full Text] [Related]
78. Correlation of serum IL-2, IL-6 and IL-10 levels with International Prognostic Index in patients with aggressive non-Hodgkin's lymphoma.
Aydin F; Yilmaz M; Ozdemir F; Kavgaci H; Yavuz MN; Yavuz AA
Am J Clin Oncol; 2002 Dec; 25(6):570-2. PubMed ID: 12478000
[TBL] [Abstract][Full Text] [Related]
79. Treatment of aggressive non-Hodgkin's lymphoma in frail patients: cardiac comorbidities and advanced age.
Lugtenburg PJ; Lyon AR; Marks R; Luminari S
Future Oncol; 2019 Apr; 15(11):1197-1205. PubMed ID: 30730219
[TBL] [Abstract][Full Text] [Related]
80. [Effect of PD-1, FOXP3 and CSF-1R Protein Expression on the Prognosis of Patients with Hodgkin's Lymphoma].
Li XJ; He L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1372-1377. PubMed ID: 30295253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
